Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine.

M Galli1, A L Ridolfo, C Balotta

  • 1Institute of Infectious Diseases, University of Milan, Italy.

AIDS (London, England)
|October 1, 1991
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive pathways to communicative-pragmatic dysfunction in schizophrenia: The role of autistic symptoms.

Schizophrenia research. Cognition·2026
Same author

Breaking barriers in extensively drug-resistant TB: pretomanid-centred long regimen achieves cure in a bedaquiline-resistant strain.

IJTLD open·2026
Same author

Profiling electrophysiological and linguistic markers: implications for clinical and functional outcome in schizophrenia.

Neuropsychologia·2025
Same author

Unilateral uveitis following adjuvanted Varicella-Zoster subunit vaccine in a patient with previously resolved Varicella Zoster acute retinal necrosis.

Journal of ophthalmic inflammation and infection·2025
Same author

Rifampicin drug monitoring in TB patients: new evidence for increased dosage?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

<i>ARID1B</i>-related disorder in 87 adults: Natural history and self-sustainability.

Genetics in medicine open·2024

Zidovudine treatment for early HIV-1 infection significantly lowers serum soluble interleukin-2 receptor (sIL-2R) levels. This reduction in sIL-2R indicates improved treatment efficacy and can be a useful monitoring tool for HIV therapy.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Early-stage Human Immunodeficiency Virus type 1 (HIV-1) infection is often characterized by elevated serum levels of soluble interleukin-2 receptor (sIL-2R).
  • Monitoring treatment efficacy in HIV-1 infection is crucial for patient management and therapeutic adjustments.

Purpose of the Study:

  • To evaluate the utility of serum soluble interleukin-2 receptor (sIL-2R) levels as a biomarker for monitoring zidovudine treatment efficacy in early HIV-1 infection.

Main Methods:

  • Comparative analysis of sIL-2R levels in HIV-1 patients treated with zidovudine versus untreated patients.
  • Prospective study monitoring sIL-2R levels in a cohort of 33 patients undergoing zidovudine therapy for 90 days.
  • Correlation analysis between sIL-2R reduction and p24 antigen negativity during zidovudine treatment.

Related Experiment Videos

Main Results:

  • Significantly lower sIL-2R levels were observed in 24 zidovudine-treated patients compared to 69 untreated patients (P < 0.0001).
  • A significant decrease in sIL-2R levels was noted in 33 subjects treated with zidovudine over 90 days (2113 +/- 1131 to 1444 +/- 728; P < 0.0007).
  • Greater reduction in sIL-2R was associated with achieving p24 antigen negativity during zidovudine therapy.

Conclusions:

  • Serum sIL-2R levels are a valuable laboratory parameter for monitoring the efficacy of zidovudine treatment in early HIV-1 infection.
  • The observed decrease in sIL-2R suggests a positive response to zidovudine therapy and a potential reduction in viral activity.